Buchumschlag

Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendum

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hofheinz, Ralf-Dieter (VerfasserIn) , Herrle, Florian (VerfasserIn) , Dechow, T. (VerfasserIn) , von Weikersthal, L. F. (VerfasserIn) , Welslau, M. (VerfasserIn) , Lettmaier, S. (VerfasserIn) , Burkart, C. (VerfasserIn) , Kubicka, S. (VerfasserIn) , Kochen, L. (VerfasserIn) , Merx, Kirsten (VerfasserIn) , Krause, K. (VerfasserIn) , Ebert, Matthias (VerfasserIn) , Rödel, C. (VerfasserIn) , Fokas, E. (VerfasserIn) , Ghadimi, M. (VerfasserIn) , Reißfelder, Christoph (VerfasserIn) , Gaiser, T. (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: February 2025
In: ESMO open
Year: 2025, Jahrgang: 10, Heft: 2, Pages: 1-1
ISSN:2059-7029
DOI:10.1016/j.esmoop.2024.104095
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2024.104095
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702924018660
Volltext
Verfasserangaben:R.-D. Hofheinz, F. Herrle, T. Dechow, L.F. von Weikersthal, M. Welslau, S. Lettmaier, C. Burkart, S. Kubicka, L. Kochen, K. Merx, K. Krause, M. Ebert, C. Rödel, E. Fokas, M. Ghadimi, C. Reissfelder & T. Gaiser

MARC

LEADER 00000naa a2200000 c 4500
001 1930430450
003 DE-627
005 20250714121037.0
007 cr uuu---uuuuu
008 250714s2025 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.esmoop.2024.104095  |2 doi 
035 |a (DE-627)1930430450 
035 |a (DE-599)KXP1930430450 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hofheinz, Ralf-Dieter  |d 1969-  |e VerfasserIn  |0 (DE-588)121917517  |0 (DE-627)08161876X  |0 (DE-576)292991568  |4 aut 
245 1 0 |a Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer  |b a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendum  |c R.-D. Hofheinz, F. Herrle, T. Dechow, L.F. von Weikersthal, M. Welslau, S. Lettmaier, C. Burkart, S. Kubicka, L. Kochen, K. Merx, K. Krause, M. Ebert, C. Rödel, E. Fokas, M. Ghadimi, C. Reissfelder & T. Gaiser 
264 1 |c February 2025 
300 |a 1 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 16. Dezember 2024, Artikelversion: 20. Februar 2025 
500 |a Gesehen am 14.07.2025 
700 1 |a Herrle, Florian  |d 1972-  |e VerfasserIn  |0 (DE-588)131457802  |0 (DE-627)509456138  |0 (DE-576)252073150  |4 aut 
700 1 |a Dechow, T.  |e VerfasserIn  |4 aut 
700 1 |a von Weikersthal, L. F.  |e VerfasserIn  |4 aut 
700 1 |a Welslau, M.  |e VerfasserIn  |4 aut 
700 1 |a Lettmaier, S.  |e VerfasserIn  |4 aut 
700 1 |a Burkart, C.  |e VerfasserIn  |4 aut 
700 1 |a Kubicka, S.  |e VerfasserIn  |4 aut 
700 1 |a Kochen, L.  |e VerfasserIn  |4 aut 
700 1 |a Merx, Kirsten  |d 1970-  |e VerfasserIn  |0 (DE-588)122413091  |0 (DE-627)70589892X  |0 (DE-576)293258910  |4 aut 
700 1 |a Krause, K.  |e VerfasserIn  |4 aut 
700 1 |a Ebert, Matthias  |d 1968-  |e VerfasserIn  |0 (DE-588)1030133522  |0 (DE-627)734827083  |0 (DE-576)377938432  |4 aut 
700 1 |a Rödel, C.  |e VerfasserIn  |4 aut 
700 1 |a Fokas, E.  |e VerfasserIn  |4 aut 
700 1 |a Ghadimi, M.  |e VerfasserIn  |4 aut 
700 1 |a Reißfelder, Christoph  |d 1975-  |e VerfasserIn  |0 (DE-588)1025566211  |0 (DE-627)722940297  |0 (DE-576)370516044  |4 aut 
700 1 |a Gaiser, T.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t ESMO open  |d [London] : Elsevier, 2016  |g 10(2025), 2 vom: Feb., Seite 1-1  |h Online-Ressource  |w (DE-627)84705344X  |w (DE-600)2844985-X  |w (DE-576)454658516  |x 2059-7029  |7 nnas  |a Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendum 
773 1 8 |g volume:10  |g year:2025  |g number:2  |g month:02  |g pages:1-1  |g extent:1  |a Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendum 
787 0 8 |i Errata zu  |a Hofheinz, Ralf-Dieter, 1969 -   |t mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer  |d 2024  |w (DE-627)1908285567 
856 4 0 |u https://doi.org/10.1016/j.esmoop.2024.104095  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S2059702924018660  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250714 
993 |a Editorial 
994 |a 2025 
998 |g 1025566211  |a Reißfelder, Christoph  |m 1025566211:Reißfelder, Christoph  |d 60000  |d 61800  |d 50000  |e 60000PR1025566211  |e 61800PR1025566211  |e 50000PR1025566211  |k 0/60000/  |k 1/60000/61800/  |k 0/50000/  |p 13 
998 |g 1030133522  |a Ebert, Matthias  |m 1030133522:Ebert, Matthias  |d 60000  |d 61100  |e 60000PE1030133522  |e 61100PE1030133522  |k 0/60000/  |k 1/60000/61100/  |p 12 
998 |g 122413091  |a Merx, Kirsten  |m 122413091:Merx, Kirsten  |d 60000  |e 60000PM122413091  |k 0/60000/  |p 10 
998 |g 131457802  |a Herrle, Florian  |m 131457802:Herrle, Florian  |d 60000  |d 61800  |d 60000  |e 60000PH131457802  |e 61800PH131457802  |e 60000PH131457802  |k 0/60000/  |k 1/60000/61800/  |k 0/60000/  |p 2 
998 |g 121917517  |a Hofheinz, Ralf-Dieter  |m 121917517:Hofheinz, Ralf-Dieter  |d 60000  |d 61200  |e 60000PH121917517  |e 61200PH121917517  |k 0/60000/  |k 1/60000/61200/  |p 1  |x j 
999 |a KXP-PPN1930430450  |e 4745998074 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["R.-D. Hofheinz, F. Herrle, T. Dechow, L.F. von Weikersthal, M. Welslau, S. Lettmaier, C. Burkart, S. Kubicka, L. Kochen, K. Merx, K. Krause, M. Ebert, C. Rödel, E. Fokas, M. Ghadimi, C. Reissfelder & T. Gaiser"]},"id":{"eki":["1930430450"],"doi":["10.1016/j.esmoop.2024.104095"]},"recId":"1930430450","physDesc":[{"extent":"1 S."}],"person":[{"family":"Hofheinz","role":"aut","given":"Ralf-Dieter","display":"Hofheinz, Ralf-Dieter"},{"display":"Herrle, Florian","given":"Florian","role":"aut","family":"Herrle"},{"given":"T.","role":"aut","family":"Dechow","display":"Dechow, T."},{"display":"von Weikersthal, L. F.","given":"L. F.","role":"aut","family":"von Weikersthal"},{"display":"Welslau, M.","given":"M.","role":"aut","family":"Welslau"},{"display":"Lettmaier, S.","given":"S.","role":"aut","family":"Lettmaier"},{"display":"Burkart, C.","role":"aut","given":"C.","family":"Burkart"},{"family":"Kubicka","given":"S.","role":"aut","display":"Kubicka, S."},{"display":"Kochen, L.","role":"aut","given":"L.","family":"Kochen"},{"family":"Merx","role":"aut","given":"Kirsten","display":"Merx, Kirsten"},{"family":"Krause","role":"aut","given":"K.","display":"Krause, K."},{"role":"aut","given":"Matthias","family":"Ebert","display":"Ebert, Matthias"},{"display":"Rödel, C.","given":"C.","role":"aut","family":"Rödel"},{"display":"Fokas, E.","given":"E.","role":"aut","family":"Fokas"},{"display":"Ghadimi, M.","family":"Ghadimi","given":"M.","role":"aut"},{"role":"aut","given":"Christoph","family":"Reißfelder","display":"Reißfelder, Christoph"},{"display":"Gaiser, T.","family":"Gaiser","role":"aut","given":"T."}],"relHost":[{"title":[{"subtitle":"cancer horizons","title":"ESMO open","title_sort":"ESMO open"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 13.06.24"],"origin":[{"dateIssuedDisp":"2016-","dateIssuedKey":"2016","publisherPlace":"[London] ; London","publisher":"Elsevier ; BMJ"}],"disp":"Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendumESMO open","recId":"84705344X","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2844985-X"],"issn":["2059-7029"],"eki":["84705344X"]},"part":{"issue":"2","text":"10(2025), 2 vom: Feb., Seite 1-1","extent":"1","pages":"1-1","volume":"10","year":"2025"},"name":{"displayForm":["European Society for Medical Oncology"]},"pubHistory":["1.2016 -"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}]}],"origin":[{"dateIssuedDisp":"February 2025","dateIssuedKey":"2025"}],"title":[{"subtitle":"a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”$d[ESMO Open 9 (2024) 103703] : corrigendum","title":"Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer","title_sort":"Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer"}],"note":["Online verfügbar: 16. Dezember 2024, Artikelversion: 20. Februar 2025","Gesehen am 14.07.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"]} 
SRT |a HOFHEINZRACORRIGENDU2025 

Ähnliche Einträge